These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28088319)

  • 21. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
    Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
    Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
    Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
    Zhang H; Ge J; Hong H; Bi L; Sun Z
    World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
    Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
    Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
    Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
    PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.
    Chen H; Shao C; Shi H; Mu Y; Sai K; Chen Z
    J Neurooncol; 2007 May; 82(3):257-62. PubMed ID: 17151930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
    Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
    Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
    Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
    Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
    Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A
    Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.